The FDA granted approval to ofatumumab (ARZERRA), a targeted antibody
against CD20, for patients with chronic lymphocytic
leukemia (CLL) who are in complete or partial
response after at least two lines of therapy.
Researchers at SciLifeLab has together with research physicians at Karolinska University Hospital and scientists at Heidelberg University identified a key player determining
response to cytarabine — the most important drug
against acute myelogenous
leukemia.